Cannabis Stocks Are Going Nowhere Fast — Even as the Underground Market Counts Billions

Cannabis equity markets are stuck. That’s the blunt assessment making the rounds in investor circles this week, and the numbers bear it out: heading into the second quarter of 2026, major cannabis stocks have failed to produce meaningful gains despite a cycle that, by almost any consumer demand metric, should be fueling optimism.

The disconnect has become one of the more stubborn puzzles in cannabis finance — and a new economic analysis out of Indiana puts that contradiction into uncomfortable relief.

The Equity Picture

Analysts tracking the cannabis sector have grown increasingly candid about the market’s inertia. Week after week, the stocks that were supposed to recover as the regulatory environment shifted have instead traded sideways, and in many cases drifted lower. Multi-state operators that expanded aggressively in 2022 and 2023 are still working through the consequences — overcapitalized balance sheets, thin margins compressed by state-by-state tax burdens, and the ongoing absence of federal reform that would unlock institutional capital at scale.

For retail investors who got in on promises of a federal rescheduling windfall, the wait has worn thin. Cannabis equities remain largely excluded from major indices, inaccessible to federally regulated funds, and subject to the punishing tax treatment of IRS Section 280E, which disallows standard business deductions for companies trafficking in Schedule I or II substances. Until the DEA finalizes rescheduling to Schedule III — a process that has now stretched past 40,000 public comments with no hard deadline — that tax drag stays in place.

The result is a market in suspended animation. Operators are posting revenue, some are generating positive EBITDA, but the capital markets aren’t rewarding them for it. The industry finds itself in a peculiar position: profitable enough to operate, not clean enough to attract the capital that would drive a genuine re-rating.

$2 Billion Reasons the Thesis Is Still Sound

And yet. Step outside the trading screens and the demand signal is loud.

Consider Indiana — a state that bans cannabis in virtually all forms, makes no exceptions for medical patients, and spends an estimated $20 million annually enforcing that prohibition. According to a new economic report, Indiana residents are spending nearly $2 billion each year on cannabis regardless.

Two billion dollars. In a prohibition state.

That money isn’t disappearing. It’s flowing out of state to Illinois dispensaries, into illicit market transactions, and — increasingly — toward the federally legal hemp-derived THC products that have carved out retail shelf space in gas stations and convenience stores from Gary to Evansville. It represents consumer demand that the legal cannabis industry is structurally prevented from capturing, and it illustrates exactly why long-term bulls on the sector haven’t abandoned their positions even as the near-term price action grinds them down.

The Indiana figure is not an outlier. Economic researchers have produced similar analyses in other prohibition or limited-access states, consistently finding that cannabis consumption continues at robust levels regardless of legal status. The demand is not created by legalization — it exists independently. Legalization redirects it, taxes it, and brings it onto regulated company balance sheets.

For investors trying to understand why cannabis equity valuations haven’t collapsed entirely despite years of underperformance, this is part of the answer. The addressable market is real, it is large, and it does not require legalization to exist. What it requires for legal operators to monetize is access — and that access is being rationed by policy, not by consumer behavior.

The Capital Market Constraint

The structural barriers to cannabis equity performance are well-documented at this point, but they bear repeating because they still dominate the investment calculus.

Federal illegality means cannabis companies can’t access the NASDAQ or NYSE, are ineligible for standard SBA loans, and face significant complications in raising institutional capital. The major U.S. MSOs trade on Canadian exchanges or over-the-counter markets, where liquidity is thinner and investor pools are smaller. Private equity has pulled back from commitments made in the sector’s euphoric expansion years, waiting for a clearer federal signal before re-engaging at scale.

The 280E tax issue alone is worth dwelling on. An operator generating $100 million in gross revenue might owe federal taxes on income that, under standard accounting, would be reduced by tens of millions in legitimate business expenses. Cannabis companies pay tax on something closer to gross profit than net income. That structural tax drag has contributed to the wave of operator bankruptcies and restructurings that has characterized the past 18 months, and it continues to weigh on valuations for surviving companies.

Rescheduling to Schedule III would end 280E applicability, immediately improving the financial profile of virtually every licensed cannabis company in the country. That potential catalyst is real — but the timeline has proven elastic in ways that have repeatedly disappointed investors who positioned early.

What Moves the Market from Here

The honest answer is that cannabis stocks probably don’t move meaningfully until one of a small number of catalysts fires: DEA finalizes rescheduling, federal banking reform (SAFER Banking) reaches a floor vote, or a new wave of state market openings creates enough revenue growth to overwhelm the tax headwinds.

Virginia is currently a live case study. A coalition of industry groups and advocates is pushing the state’s governor to sign an adult-use sales bill that would open one of the East Coast’s larger consumer markets to licensed retail. A signature there would represent real addressable revenue for operators positioned in the state — the kind of tangible business development that, in theory, equity markets should price in.

Indiana is unlikely to move anytime soon given its legislative posture, but the $2 billion spending figure will be used by reform advocates and industry lobbyists as evidence that prohibition is an economic policy failure as much as a social one. As more states run similar analyses, the political math shifts — incrementally.

For now, investors holding cannabis equities are holding an asset class that tracks political calendar rather than consumer demand. The demand is there — it has always been there. What the stocks need is a policy environment that lets companies actually build businesses around it.

Until that changes, the weekly newsletters will keep reporting the same story: going nowhere quickly.

Caleb Quinn covers cannabis business, capital markets, and industry trends for CannabisInquirer.com.